ALB and neoplasm: Of those, 4-(p-iodophenyl)butyryl and 4-(p-methoxyphenyl)butyryl were the most preferred albumin binding domains due to the aforementioned studies, in which enhanced tumor uptake and tumor-to-kidney dose ratio were observed.